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Abstract
Background: Some patients with chronic kidney disease do not respond adequately to erythropoiesis-stimulating
agent (ESA) treatment; these patients are referred to as ESA hyporesponders. There is no widely accepted
contemporary definition for chronic ESA hyporesponse. The study objective was to propose and validate an
operational definition for chronic ESA hyporesponse.
Methods: This was a retrospective cohort study using electronic health care records. Participants were anemic
hemodialysis patients treated during February 2012 and were followed for 15 months. Patients’ ESA response
(responders) or lack of response (chronic and acute hyporesponders) based on longitudinal patterns of ESA dose
and hemoglobin level was assessed. Persistence of hyporesponse, longitudinal iron measures, transfusion rates, and
mortality rates were analyzed. Frequency of blood transfusions (monthly) and death rates (quarterly) were
calculated. Log normalized serum ferritin concentration was analyzed.
Results: Of 97,677 eligible patients, 6632 had acute hyporesponsiveness (ESA responsiveness restituted in≤ 4 months)
and 3086 had chronic hyporesponsiveness (lack of ESA response for > 4 months). Over months 1–4 among chronic
hyporesponders, mean serum ferritin (722–785 ng/mL) and transferrin saturation (TSAT; 26.76 %-27.08 %) were constant,
while acute hyporesponsive patients experienced increased ferritin (654-760 ng/mL) and TSAT (25.71–30.88 %) levels.
Compared to ESA responders (0.19–0.30 %), chronic hyporesponders were transfused 7-times (1.20–2.17 %) more
frequently over follow-up. Quarterly mortality was greatest in chronic ESA hyporesponders (2.98–5.48 %), followed by
acute ESA hyporesponders (2.17–3.30 %) and ESA responders (1.43–2.49 %). With consistence over the study, chronic
hyporesponders died more frequently than patients in the other study cohorts.
Conclusions: Findings indicate that 4 months of continuous ESA hyporesponsiveness can be used to differentiate acute
from chronic hyporesponsiveness. This definition of chronic hyporesponsiveness is supported by outcome data showing
higher mortality and transfusion rates in chronic hyporesponders compared to acute hyporesponders.
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Background
Anemia is a common complication in patients with
chronic kidney disease and end-stage renal disease
(ESRD). It is estimated that at any time approximately
85 % of hemodialysis patients in the United States are
treated with erythropoiesis-stimulating agents (ESAs) [1]
such as epoetin alfa, which are recombinant human bio-
logic products of the peptide hormone erythropoietin.
Erythropoietin and ESAs enhance red blood cell pro-
duction in the bone marrow, subsequently increasing
hemoglobin thereby avoiding transfusion in treated
patients. ESA dose is titrated to target a desired
hemoglobin concentration [2]. The doses of ESA ne-
cessary to achieve a specific hemoglobin concentration
can fluctuate with patient circumstances such as the
occurrence of infections, illnesses and hospitalizations,
and changes in iron stores [3–5].
ESA resistance, or hyporesponsiveness, is a state in
which hemoglobin response is less than typically
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anticipated for a given dose of ESA [6–8]. ESA hypore-
sponsiveness is associated with a higher risk of all-cause
mortality [6, 9, 10], and may be acute (i.e., occurs for
some duration and then remits) or chronic (i.e., persists
on a permanent or semi-permanent basis) [11]. Escal-
ation of ESA dose in hyporesponders does little to
ameliorate anemia [12]. In fact, data suggest that high
levels of ESAs used in these patients may be associated
with adverse clinical outcomes such as stroke and vascu-
lar access thrombosis [2, 13, 14]. Nonetheless, high-dose
ESAs are commonly administered to hyporesponders at
great cost to the health care system [1] and to the
possible detriment of patients.
There is no consensus, or definition, of what constitutes
ESA hyporesponsiveness in general or chronic ESA hypo-
responsiveness in particular [15]. In the past, ESA hypore-
sponsiveness was defined as requirement for a requisite
minimum dose of ESA in order to maintain hemoglobin
in the target range (i.e., 10–12 g/dL) [16] or failure to
reach the target range despite such a dose [17, 18]. How-
ever, revised anemia guidelines from Kidney Disease
Improving Global Outcomes (KDIGO) no longer specify a
lower hemoglobin target bound, complicating application
of such definitions [15]. Even prior to guideline changes,
definitions of chronic ESA hyporesponsiveness were het-
erogeneous [19]. A lack of definitional consistency impedes
interpretation of the literature and creates barriers to subse-
quent research aimed at characterizing the burden of, and
potential treatments for, chronic ESA hyporesponsiveness.
The objective of the current study was to develop and
validate an empiric definition of chronic ESA hyporespon-
siveness. A prerequisite was to first create baseline criteria
for ESA hyporesponsiveness that are applicable in con-
temporary nephrology practice. Subsequently, these cri-
teria for ESA hyporesponsiveness were applied over time
to determined whether lack of ESA response was acute
(transient) or chronic (persistent).
Methods
Setting, patients, and data source
We conducted a retrospective cohort study of a clinical
database containing the electronic medical records of
approximately 170,000 dialysis patients treated at over
2000 US dialysis facilities annually within a large dialysis
organization. Since this was a retrospective, observa-
tional study, informed patient consent was not required
and the analysis was exempt from institutional review
board or ethics committee approval. An exemption of
consent was granted by Quorum Investigational Review
Board based in Seattle due to low/minimal risk for dis-
closure of personal health information. The database
captures patient demographics, injectable medications
(e.g., ESA, intravenous iron, and vitamin D), clinical la-
boratory values, dialysis treatment records, and all
comorbidities available to the dialysis units. Patient data
are anonymized. Our study included monthly patient-
level data for a 15-month period between 01 February
2012 and 30 April 2013. Patients included in the analysis
were ≥ 18-years old as of 01 February 2012 and had been
receiving thrice weekly in-center hemodialysis prior to 01
February 2012. Patients were excluded if they were receiv-
ing peritoneal dialysis, home hemodialysis, or nocturnal
hemodialysis; had a documented history of cancer; or were
currently receiving cancer treatment. To minimize the im-
pact of acute illness on hyporesponse measures, patients
were also excluded if they were hospitalized during Janu-
ary 2012, the month prior to baseline assessments.
Operational baseline criteria for ESA hyporesponse
To inform baseline criteria for ESA hyporesponsiveness
we examined data from month 1 of the study (baseline
month of February 2012). We calculated individual pa-
tients’ mean hemoglobin concentrations and per adminis-
tration ESA doses (cumulative monthly dose divided by
the number of scheduled in-center hemodialysis treat-
ments). These values were cross tabulated to characterize
the distribution of patients’ hemoglobin-by-ESA dose
strata. Patients may have missed dialysis sessions for a var-
iety of reasons, however, these sessions are not included in
the per session ESA dose calculation. We identified a
series of contiguous strata that were logically consistent
with ESA hyporesponsiveness. Each specified stratum was
characterized by ESA dose > 72nd percentile for the cohort
(corresponding to > 4000 erythropoietin U/treatment).
Increasingly restrictive thresholds for ESA dose were re-
quired for strata characterized by higher hemoglobin:
e.g., for hemoglobin > 9.5 to 10 g/dL ESA dose threshold
was > 6000 U/treatment (i.e., > 84th percentile); for
hemoglobin > 10 to 10.5 g/dL ESA dose threshold was >
8000 U/treatment (i.e., > 89th percentile); for
hemoglobin > 10.5 to 11 g/dL ESA dose threshold was >
10,000 U/treatment (i.e., > 93rd percentile), etc. Patients
identified using this hemoglobin-by-ESA dose strata
were identified as ESA hyporesponders. The type of the
hyporesponse (acute vs. chronic) was determined by
considering patients’ hemoglobin-by-ESA dose strata
over time.
Longitudinal definitions of ESA hyporesponse
The definition of chronic ESA hyporesponsiveness was
based on the consideration: after how many months of
consecutive hyporesponsiveness is it unlikely that patients
will subsequently regain ESA responsiveness? For this
study, we considered all patients who met criteria for
ESA hyporesponse at baseline and conducted a Kaplan
Meier analysis to characterize time to restitution of ESA
responsiveness (i.e., the first month in which each pa-
tient no longer met the baseline criteria for ESA
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hyporesponse). We used these results to identify the
month that the Kaplan Meier curve flattened, at which
time restitution of ESA responsiveness was unlikely, and
thereby defining a minimum requirement for chronic
hyporesponsiveness. It should be noted that this defin-
ition is consistent with previous evidence generated at
the time of data analysis by Gilbertson et al. 2013. Pa-
tients who were ESA hyporesponse but in whom hypor-
esponse did not persist for this requisite duration were
categorized as acute hyporesponders.
Patients were characterized into 3 mutually exclusive
categories for analysis: 1) ESA responders, who did not
meet criteria for ESA hyporesponse in month 1; 2) acute
ESA hyporesponders, who met criteria for ESA hypore-
sponse in month 1 of study but in whom ESA hypore-
sponse did not persist long enough thereafter to qualify as
chronically ESA hyporesponsive; 3) chronic ESA hypore-
sponders, who met criteria for ESA hyporesponse in
month 1 of study and in whom ESA hyporesponse lasted
long enough to qualify as persistent according to Kaplan
Meier analysis.
Comparisons among chronic ESA hyporesponders, acute
ESA hyporesponders, and ESA responders
Among these 3 groups we compared baseline demo-
graphic, comorbidity, and laboratory characteristics. Fer-
ritin and transferrin saturation (TSAT) levels were
compared over months 1 through 4 of study (i.e., the
period of time over which distinctions between acute
and chronic hyporesponse were made). These iron indi-
ces were studied to examine whether iron stores differed
between acute and chronic ESA hyporesponders and
may have contributed to ESA hyporesponse. Transfusion
rates were compared among study groups over months
1 through 7. Transfusion data, which were obtained by a
third-party vendor from inpatient records, were not
available after August 2013. Finally, quarterly mortality
rates were compared among study groups; to avoid im-
mortal time bias, mortality was considered beginning in
month 5 (i.e., after the distinction between acute and
chronic ESA hyporesponse was made).
Statistical methods
Categorical variables were characterized as counts and
proportions. Continuous variables were characterized as
means, standard deviations, medians, and ranges.
Kaplan Meier analysis was conducted to determine the
time to restitution for ESA responsiveness among patients
who met criteria for ESA hyporesponse in month 1.
Linear mixed models were used to compare mean fer-
ritin, mean TSAT, and transfusion rates. Ferritin values
were skewed and therefore were log transformed; results
were then presented on the actual scale. Transfusions
were categorized as dichotomous (yes, no) for each
patient-month based on whether the patient received
any red blood cell transfusions during the month; results
were expressed as the proportion of patients transfused.
Mortality was analyzed by life-table methods using quar-
terly intervals beginning in study month 5. For all ana-
lyses, patients were censored at the time of transfer of
care, kidney transplant, dialysis modality change, with-
drawal from dialysis, or death.
Results
A total of 97,677 patients were identified as eligible for the
analysis. Of those, 10,825 (11.08 %) patients met criteria
for ESA hyporesponse in month 1 (baseline, February
2012) of the study (Table 1). For internal validation pur-
poses, we performed a similar analysis for the month of
July 2011 (a time during which ESA dosing in ESRD was
substantially different [20–22]) and observed a similar
proportion of patients who met the criteria for ESA hypor-
esponse (11.56 %) (Additional file 1: Table S1).
Figure 1 shows the Kaplan Meier cumulative survival
plot. It illustrates the time to restitution of ESA response
in months. For the majority of patients (61.3 %), ESA re-
sponsiveness was regained by month 4; thereafter, the
curve reached a plateau. Based on this finding, acute ESA
hyporesponse was defined as hyporesponse lasting <
4 months, and chronic ESA hyporesponse was defined as
hyporesponse persisting ≥ 4 months.
Of the 10,825 baseline hyporesponders 1107 were cen-
sored by the end of month 4 (127 were lost to follow up,
55 received kidney transplants, 2 had dialysis modality
changes, 500 had transfer of care, and 423 died). Of the
remaining 9718 baseline hyporesponders, 6632 (68.2 %)
were acute hyporesponders and 3086 (31.8 %) were
chronic hyporesponders. Of 97,677 patients available at
baseline, 81,504 ESA responders were still available for
study through the end of month 4 and available for sub-
sequent analyses.
Baseline demographic characteristics for chronic hypor-
esponders, acute hyporesponders, and ESA responsive pa-
tients are shown in Table 2 (continuous variables) and
Table 3 (categorical variables). The mean age was lower
for chronic hyporesponders (58.8 years) versus acute
hyporesponders (60.1 years) versus responders (62.4 years).
Dialysis vintage varied between 3.8 and 4.1 years across all
3 groups. Chronic ESA hyporesponders had higher mean
body mass index (29.1 kg/m [2]) than the other 2 groups.
At baseline, ESA responders had higher mean hemoglobin
(11.0 g/dL) and TSAT (31.8 %) than either acute or
chronic hyporesponders, who were similar to one another.
Minor differences in median serum ferritin were observed
among study groups at baseline: 748, 731, and 757 ng/mL
for chronic hyporesponders, acute hyporesponders, and
responders, respectively. Sex and racial mix were similar
across all 3 groups. Chronic (21.7 %) and acute (23.8 %)
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Table 1 Baseline distribution of ESA dose by hemoglobin concentration: February 2012
ESA Dose Per Session (IU) Range
Missing 0- 2000 >2000-4000 >4000-6000 >6000-8000 >8000-10,000 >10,000-12,000 >12,000-14,000 >14,000-16,000 >16,000
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
Hemoglobin
Range (g/dL)
Missing 0.18 (174) 0.12 (113) 0.13 (128) 0.12 (116) 0.06 (56) 0.06 (59) 0.03 (29) 0.02 (15) 0.04 (38) 0.01 (14) 0.76 (742)
<8 0.02 (18) 0.02 (16) 0.04 (36) 0.05 (49) 0.05 (47) 0.05 (49) 0.04 (43) 0.05 (53) 0.14 (137) 0.11 (109) 0.57 (557)
>8-8.5 0.02 (21) 0.04 (36) 0.13 (128) 0.13 (128) 0.10 (94) 0.09 (92) 0.06 (57) 0.08 (82) 0.15 (151) 0.11 (111) 0.92 (900)
>8.5-9 0.03 (34) 0.16 (156) 0.37 (366) 0.34 (336) 0.23 (226) 0.17 (170) 0.16 (159) 0.17 (163) 0.23 (225) 0.11 (111) 1.99 (1946)
>9-9.5 0.06 (59) 0.57 (552) 1.15 (1124) 0.82 (802) 0.46 (452) 0.33 (327) 0.26 (253) 0.25 (242) 0.31 (299) 0.15 (149) 4.36 (4259)
>9.5-10 0.11 (109) 1.92 (1872) 2.85 (2780) 1.64 (1601) 0.86 (842) 0.61 (596) 0.34 (330) 0.36 (355) 0.34 (351) 0.15 (160) 9.21 (8996)
>10-10.5 0.36 (352) 5.44 (5310) 5.09 (4975) 2.56 (2504) 1.18 (1155) 0.88 (856) 0.49 (477) 0.33 (326) 0.32 (314) 0.14 (135) 16.80 (16,404)
>10.5-11 1.0 (979) 10.06 (9828) 6.19 (6050) 2.81 (2744) 1.36 (1327) 0.89 (866) 0.34 (335) 0.22 (212) 0.16 (158) 0.07 (73) 23.11 (22,572)
>11-11.5 1.94 (1892) 10.25 (10,010) 4.34 (4236) 1.96 (1918) 0.95 (930) 0.52 (505) 0.19 (185) 0.08 (78) 0.04 (36) 0.05 (48) 20.31 (19,838)
>11.5-12 2.88 (2811) 5.24 (5115) 1.91 (1868) 0.79 (733) 0.35 (343) 0.14 (137) 0.07(68) 0.02 (19) 0.01 (12) 0.02 (15) 11.43 (11,161)
>12 6.75 (6593) 1.98 (1936) 0.97 (951) 0.48 (469) 0.18 (180) 0.09 (85) 0.04 (43) 0.01 (16) 0.01 (12) 0.10 (7) 10.54 (10,292)
13.35 (13,042) 35.78 (34,944) 23.18 (22,642) 11.71 (11,440) 5.79 (5652) 3.83 (3742) 2.03 (1979) 1.60 (1561) 1.77 (1733) 0.95 (932) 100 (97,677)











Fig. 1 Shown is a Kaplan Meier analysis illustrating hemodialysis patients’ return to ESA responsiveness according to ESA dose by hemoglobin
concentrations for all patients who were hyporesponsive at month 1 (baseline). +Indicates censoring during month for transfer of care, kidney
transplant, dialysis modality change, withdrawal from dialysis, or death
Table 2 Comparison of baseline characteristics among ESA responders, acute hyporesponders, and chronic hyporesponders:
continuous variables
Chronic hyporesponders (n = 3086) Acute hyporesponders (n = 6632) ESA responders (n = 81,504) P value
Mean SD Median Mean SD Median Mean SD Median
Age (years) 58.8 14.8 59.3 60.1 14.8 61.0 62.4 14.7 63.1 <.0001
Vintage (years) 4.1 3.9 3.1 3.8 3.8 2.8 3.9 3.8 2.9 <.0001
BMI (kg/m2) 29.1 8.4 27.1 28.2 7.6 26.6 28.2 7.2 26.8 .0003
Hb (g/dL) 9.5 1.0 9.6 9.8 0.9 9.8 11.0 1.0 11.0 <.0001
Ferritin (ng/mL) 834 671 748 773 471 731 776 409 757 <.0001
TSAT (%) 29.0 16.7 25.0 29.1 16.5 25 31.8 13.6 29.0 <.0001
Albumin (g/dL) 3.8 0.5 3.8 3.8 0.5 3.9 4.0 0.4 4.0 <.0001
Phosphorus (mg/dL) 5.3 1.5 5.1 5.1 1.5 5.0 5.1 1.4 4.9 <.0001
Calcium (mg/dL) 9.1 0.7 9.1 9.1 0.7 9.1 9.1 0.6 9.1 <.0001
PTH (pg/mL) 561 662 387 494 478 374 442 371 354 <.0001
CRP (mg/L) 5.8 3.9 5.4 6.5 7.8 3.3 2.9 5.6 0.9 .0157
Charlson Comorbidity Index 5.2 2.0 5.0 5.3 1.9 5.0 5.5 1.9 6 <.0001
BMI body mass index, CRP C-reactive protein, ESA, erythropoietin-stimulating agent, Hb hemoglobin, PTH parathyroid hormone, SD standard deviation,
TSAT transferrin saturation
P values represent a Kruskal Wallis one way analysis of variance test
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hyporesponders were more commonly dialyzed via a cen-
tral venous catheter than ESA responders (14.0 %).
In order to examine a potential role of iron deficiency in
mediating ESA hyporesponse, mean TSAT and serum fer-
ritin were studied longitudinally (Fig. 2). Over months 1
through 4, among chronic hyporesponders, mean TSAT
(range 27.08 to 26.76 %) and ferritin (range 772 to
786 ng/mL) remained relatively constant (Fig. 2). For acute
hyporesponders, mean TSAT increased (26.01 to 30.88 %)
and mean ferritin decreased and then increased to levels
greater than baseline (722 to 654 to 760 ng/mL).
Figure 3 shows the monthly frequency of transfusion
among study groups over follow-up. Compared to ESA
responders, on average chronic ESA hyporesponders had
approximately 7-fold higher monthly burden of transfu-
sion (range of 0.19 to 0.30 % versus 1.20 to 2.17 %, re-
spectively). Acute hyporesponders had a 5-fold greater
transfusion burden than responders initially (0.97 versus
Table 3 Comparison of baseline characteristics among ESA responders, acute hyporesponders, and chronic hyporesponders:
categorical variables
Chronic hyporesponders (n = 3086) Acute hyporesponders (n = 6632) ESA responders (n = 81,504) p-value
N % N % N %
Gender female 1633 52.9 3395 51.2 44,700 54.8 <0.0001
Race/ethnicity <0.0001
American Indian 25 0.8 68 1.0 1153 1.4
Asian 94 3.1 237 3.6 3063 3.8
Black 1339 43.4 2806 42.3 30,309 37.2
Hispanic 342 11.1 961 14.5 15,162 18.6
Pacific Islander 25 0.8 49 0.7 708 0.9
Other 204 6.6 432 6.5 4222 5.2
White 1057 34.3 2079 31.4 26,887 33.0
Primary cause renal disease <0.0001
Diabetes 1182 38.0 2769 41.8 35,969 44.1
Hypertension 901 29.2 1981 29.9 24,936 30.6
Vascular access <0.0001
Fistula 1726 55.9 3732 56.3 53,200 65.3
Catheter 671 21.7 1579 23.8 11,382 14.0
Graft 685 22.2 1321 19.9 16,904 20.7
Other 4 0.1 0 0 17 0.02
Diabetes 1558 50.5 3389 51.1 43,279 53.1 0.0001
Hypertension 1114 36.1 2401 36.2 28,282 34.7 0.0174
Cardiac arrest 3 0.1 7 0.1 82 0.1 0.9929
Myocardial infarction 9 0.3 13 0.2 163 0.2 0.1776
COPD 160 5.2 298 4.5 3097 3.8 <0.0001
History of GI bleed 68 2.2 73 1.1 815 1.0 <0.0001
Liver disease 71 2.3 126 1.9 1304 1.6 0.0009
HIV/AIDS 28 0.9 53 0.8 326 0.4 <0.0001
Hepatitis B 22 0.7 27 0.4 245 0.3 <0.0001
Septicemia 241 7.8 484 7.3 4646 5.7 <0.0001
Pneumonia 108 3.5 206 3.1 1875 2.3 <0.0001
Anemia hemolytic/sickle cell 68 2.2 33 0.5 245 0.3 <0.0001
Myelodysplastic syndrome 40 1.3 27 0.4 82 0.1 <0.0001
Monoclonal gammopathy 22 0.7 33 0.5 326 0.4 0.0006
COPD chronic obstructive pulmonary disorder, ESA erythropoietin-stimulating agent, GI gastrointestinal, HIV/AIDS Human Immunodeficiency Virus/Acquired
Immunodeficiency Syndrome
P-values represent a chi square test
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0.19 %) that appeared to decrease with recovery of ESA
responsiveness (0.56 versus 0.27 %) in later months.
Quarterly mortality data among study groups are pre-
sented in Table 4. Mortality rate was greatest in chronic
ESA hyporesponders, followed by acute ESA hyporespon-
ders, and ESA responders. On average, quarterly mortality
was approximately 2.2-fold greater in chronic hyporespon-
ders than responders, and remained persistently elevated
among chronic ESA hyporesponders over the remaining
quarters (range 2.98 to 5.48 %). Overall mortality was ap-
proximately 1.4-fold greater in acute hyporesponders than
responders, although differences between them dimin-
ished with time (acute ESA hyporesponders range 2.17 to
3.30 %; ESA responders range 1.43 to 2.49 %).
Discussion
The results of our analyses were used to define chronic





Fig. 2 Iron storage indices are illustrated for acute and chronic ESA hyporesponsive patients over months 1 (baseline) through 4. Mean serum
ferritin concentrations are shown in panel a (log transformed values of asymmetrically distributed ferritin values among patients). Mean percent
TSAT are shown in panel b
Fig. 3 The percentage of patients who received transfusions during follow up are depicted. Results are shown for ESA responders, and acute and
chronic ESA hyporesponders
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hyporesponse in hemodialysis patients receiving ESA for
renal anemia. Fundamental to defining chronic ESA
hyporesponse was first determining what constituted
ESA hyporesponse.
Studies designed to characterize or predict ESA hypore-
sponse have used differing methods to define it. For ex-
ample, in their 10-year long study of incident hemodialysis
and peritoneal dialysis patients, Suttorp et al. defined ESA
resistance as hemoglobin level < 11 g/dL with an above
median ESA dose depending on the method of adminis-
tration (intravenous in HD patients or subcutaneous in
PD patients) [23]. Others have chosen to determine ESA
hyporesponse singularly by dose. In a post-hoc analysis
Rossert et al. identified any patient as a hyporesponder
who received subcutaneous ESA doses of > 100 IU/kg/
week at any time over a 4-month dose-stabilization period
[24]. Inrig et al. identified patients as ESA hyporesponders
who received ≥1 μg/kg/week of darbepoetin [25]. Others
have chosen to consider both patient ESA dose and
hemoglobin level expressed as erythropoietin resistance
index ([ERI] IU/kg/week divided by hemoglobin in g/dL)
with varying ERI thresholds for analysis: Lopez-Gomez
et al. prospectively stratified their analysis of factors that
condition ESA response by creating ERI groups of < 5, 5–
15, and > 15 [26]. In their descriptive analysis, Nishio et al.
calculated the ERIs of hemodialysis patients and analyzed
ESA hyporesponse by tertiles, finding that regardless of
the ERI cut-off value used for study, a higher risk of death
was apparent for patients falling above the chosen thresh-
old than below it [27]. And in their meta analysis of
erythropoietin resistance, authors used diverse definitions
for erythropoietin resistance in patients who were not
malnourished nor suffering from bleeding disorders in-
cluding among others, ≥ 450 IU/kg/week intravenous or ≥
300 IU/kg/week subcutaneous erythropoietin, and ≥
1.5 μg/kg/week of darbepoetin [28].
In our analysis, we defined chronic ESA hyporesponse
and attempted to differentiate it from acute hypore-
sponse taking into consideration both hemoglobin level
and ESA dose. Criteria for chronic hyporesponse must
consider the dramatic evolution of anemia management
that has occurred over recent years in the United States
[20, 22]. Here we identified a series of contiguous ESA
dose-by-hemoglobin strata that are logically consistent
with ESA hyporesponse and ESA dosing distributions in
hemodialysis patients. Our findings are strengthened by
the fact that the proportion of patients identified as ESA
hyporesponsive was similar prior to (July 2011) and
following the recent changes in ESA dosing patterns
(February 2012) [20, 22]. Building on these criteria for
hyporesponse, we observed that most patients who were
identified as hyporesponsive at baseline (month 1) but
went on to recover ESA responsiveness, did so by month
4. Results from our Kaplan Meier analysis demonstrated
that after more than 4 months of meeting the baseline
definition of ESA hyporesponsiveness subsequent recov-
ery of ESA responsiveness was less likely, thereby pro-
viding an empiric based definition of chronic ESA
hyporesponsiveness.
Recently, Gilbertson et al. proposed a definition of
chronic ESA hyporesponse of ≥ 4 consecutive months of
elevated ESA dose greater than the ninetieth percentile
(176,400 IU monthly, approximately 13,500 U/treatment)
[11]. It is reassuring that when methodologies different
than ours were used to identify ESA hyporesponse,
4 months was determined as the requisite period necessary
to characterize it as chronic. However, the Gilbertson et al.
study was conducted with hemodialysis patient data gener-
ated during 2008, and the ESA dose criteria do not reflect
changes in ESA dosing that have occurred since 2011.
The many medical conditions that contribute to
anemia in patients with chronic kidney disease are prob-
ably the same factors that determine the nature of ESA
hyporesponse [19], such as inflammation [7, 12, 25],
prevalent comorbidities [7, 26], and medications [29], as
well as iron deficiency [29, 30]. Iron deficiency may in-
fluence ESA hyporesponse in some dialysis patients, and
has been associated with reduced TSAT in patients with
hyporesponse [26, 29–31]. However, we did not find evi-
dence of widespread inadequate iron stores among ESA
hyporesponsive patients [7]. In our study, mean ferritin
levels were > 650 ng/mL in both acute and chronic ESA
hyporesponders. Among acute hyporesponders, iron de-
ficiency may have played somewhat of a mediating role:
Table 4 Quarterly mortality among ESA responders, acute hyporesponders and chronic hyporesponders
Chronic Hyporesponders Acute Hyporesponders ESA Responders P Value
Q1 (Months 5–7) % deaths 5.48 % (169/3086) 2.97 % (197/6632) 2.00 % (1631/81,504) <0.0001
Q2 (Months 8–10) % deaths 4.56 % (125/2741) 3.06 % (189/6167) 2.16 % (1671/77,451) <0.0001
Q3 (Months 11–13) % deaths 4.61 % (115/2497) 3.30 % (186/5723) 2.49 % (1834/73,559) <0.0001
Q4 (Months 14, 15) % deaths 2.98 % (67/2250) 2.17 % (116/5334) 1.43 % (997/69,478) <0.0001
Quarterly mortality was calculated by dividing the total number of deaths over the time period divided by the number of patients alive at the beginning of the
time period who were not censored for discontinuation, modality change, or transplant/failed transplant. To avoid immortal time bias, mortality was considered
beginning in month 5 (i.e., after the distinction between acute and chronic ESA hyporesponsiveness could be made); patients who died or were censored before
4 months had elapsed were excluded from analyses
P values represent a chi square test
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TSAT levels rose concurrently with restitution of ESA
responsiveness. Conversely, among chronic ESA hypore-
sponders, TSAT levels were constant over time, and in
excess of 20 %, not suggestive of relative iron deficiency
in this group.
Decades after the introduction of ESAs to treat anemia
of renal disease, the rationale for transfusion avoidance
is still valid [32], but for patients suffering from ESA
hyporesponse, our data demonstrate that red cell trans-
fusion may become an undesirable necessity [15]. Of
great importance is the finding that transfusion burden
was distinct among ESA responsive, acute hyporespon-
sive, and chronic hyporesponsive patients. There was a
graded transfusion risk among the 3 patient groups, with
the greatest in patients who would go on to become cate-
gorized as chronic hyporesponders and lowest in ESA re-
sponsive patients. Moreover, whereas the difference
between acute hyporesponders and responders in fre-
quency of transfusion diminished over time, the frequency
of transfused patients among chronic hyporesponders
remained persistently higher than the other groups.
Low hemoglobin concentration [6, 33–35] and high
erythropoietin requirement has been associated with
mortality in patients with renal anemia [6, 23, 26, 30].
Our study findings also indicated a graded pattern of
mortality, with chronically hyporesponsive patients hav-
ing greater mortality rates than acutely hyporesponsive
patients, each of which had greater mortality rates than
patients with ESA responsiveness. The higher rate of
mortality for patients with chronic ESA hyporesponsive-
ness persisted for at least 9 months, well beyond the
requisite 4-month period over which chronic hypore-
sponsiveness was defined. By contrast, mortality differ-
ences between acute hyporesponsive patients and ESA
responsive patients abated with time.
A number of limitations inherent to observational re-
search apply to our analysis. Over the 15-month study
period it is possible that new illnesses emerged that were
not identified at the baseline month, potentially confound-
ing results. Another limitation is that all data were taken
from a single dialysis provider organization, and its clinical
patient database may have been missing some patient his-
tory and prior diagnoses information. Furthermore, we did
not exclude conditions that are likely to be associated with
hyporesponsiveness, e.g., gastrointestinal bleeds (a major
cause of hyporesponsiveness) and patients with myelodys-
plastic syndrome. However, these conditions as captured in
our database are exceedingly rare. Therefore generalization
of our study findings to all hemodialysis patient popula-
tions is not guaranteed. However, this concern is allayed
somewhat given that this provider cares for approximately
one third of all hemodialysis patients in the United States,
and that our results are in agreement with other research
around chronic ESA hyporesponse [11].
Conclusions
Our study findings demonstrate that chronic ESA hypor-
esponse is distinct from acute hyporesponse and can be
defined using hemoglobin levels and ESA dose as hypor-
esponse that persists for at least 4 months. Chronic ESA
hyporesponsive patients have persistently greater bur-
dens of transfusion and death compared to other pa-
tients. Additional studies are needed to further validate
our definitions and to test their generalizability to other
hemodialysis populations.
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